BACKGROUND AND PURPOSE: The KCNQ-encoded voltage-gated potassium channel family (Kv 7.1-Kv 7.5) are established regulators of smooth muscle contractility, where Kv 7.4 and Kv 7.5 predominate. Various Kv 7.2-7.5 channel enhancers have been developed that have been shown to cause a vasorelaxation in both rodent and human blood vessels. Recently, two novel Kv 7 channel enhancers have been identified, ML213 and NS15370, that show increased potency, particularly on Kv 7.4 channels. The aim of this study was to characterize the effects of these novel enhancers in different rat blood vessels and compare them with Kv 7 enhancers (S-1, BMS204352, retigabine) described previously. We also sought to determine the binding sites of the new Kv 7 enhancers. KEY RESULTS: Both ML213 and NS15370 relaxed segments of rat thoracic aorta, renal artery and mesenteric artery in a concentration-dependent manner. In the mesenteric artery ML213 and NS15370 displayed EC50 s that were far lower than other Kv 7 enhancers tested. Current-clamp experiments revealed that both novel enhancers, at low concentrations, caused significant hyperpolarization in mesenteric artery smooth muscle cells. In addition, we determined that the stimulatory effect of these enhancers relied on a tryptophan residue located in the S5 domain, which is the same binding site for the other Kv 7 enhancers tested in this study. CONCLUSIONS AND IMPLICATIONS: This study has identified and characterized ML213 and NS15370 as potent vasorelaxants in different blood vessels, thereby highlighting these new compounds as potential therapeutics for various smooth muscle disorders.
BACKGROUND AND PURPOSE: The KCNQ-encoded voltage-gated potassium channel family (Kv 7.1-Kv 7.5) are established regulators of smooth muscle contractility, where Kv 7.4 and Kv 7.5 predominate. Various Kv 7.2-7.5 channel enhancers have been developed that have been shown to cause a vasorelaxation in both rodent and human blood vessels. Recently, two novel Kv 7 channel enhancers have been identified, ML213 and NS15370, that show increased potency, particularly on Kv 7.4 channels. The aim of this study was to characterize the effects of these novel enhancers in different rat blood vessels and compare them with Kv 7 enhancers (S-1, BMS204352, retigabine) described previously. We also sought to determine the binding sites of the new Kv 7 enhancers. KEY RESULTS: Both ML213 and NS15370 relaxed segments of rat thoracic aorta, renal artery and mesenteric artery in a concentration-dependent manner. In the mesenteric artery ML213 and NS15370 displayed EC50 s that were far lower than other Kv 7 enhancers tested. Current-clamp experiments revealed that both novel enhancers, at low concentrations, caused significant hyperpolarization in mesenteric artery smooth muscle cells. In addition, we determined that the stimulatory effect of these enhancers relied on a tryptophan residue located in the S5 domain, which is the same binding site for the other Kv 7 enhancers tested in this study. CONCLUSIONS AND IMPLICATIONS: This study has identified and characterized ML213 and NS15370 as potent vasorelaxants in different blood vessels, thereby highlighting these new compounds as potential therapeutics for various smooth muscle disorders.
Authors: Thomas A Jepps; Iain A Greenwood; James D Moffatt; Kenton M Sanders; Susumu Ohya Journal: Am J Physiol Gastrointest Liver Physiol Date: 2009-04-23 Impact factor: 4.052
Authors: Preet S Chadha; Friederike Zunke; Alison J Davis; Thomas A Jepps; Joannes T M Linders; Michael Schwake; Rob Towart; Iain A Greenwood Journal: Br J Pharmacol Date: 2012-06 Impact factor: 8.739
Authors: Preet S Chadha; Friederike Zunke; Hai-Lei Zhu; Alison J Davis; Thomas A Jepps; Søren P Olesen; William C Cole; James D Moffatt; Iain A Greenwood Journal: Hypertension Date: 2012-02-21 Impact factor: 10.190
Authors: S Y M Yeung; V Pucovský; J D Moffatt; L Saldanha; M Schwake; S Ohya; I A Greenwood Journal: Br J Pharmacol Date: 2007-05-21 Impact factor: 8.739
Authors: William Dalby-Brown; Carsten Jessen; Charlotte Hougaard; Marianne L Jensen; Thomas A Jacobsen; Karin S Nielsen; Helle K Erichsen; Morten Grunnet; Philip K Ahring; Palle Christophersen; Dorte Strøbæk; Susanne Jørgensen Journal: Eur J Pharmacol Date: 2013-04-03 Impact factor: 4.432
Authors: A Rostock; C Tober; C Rundfeldt; R Bartsch; J Engel; E E Polymeropoulos; B Kutscher; W Löscher; D Hönack; H S White; H H Wolf Journal: Epilepsy Res Date: 1996-04 Impact factor: 3.045
Authors: Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; William A Catterall; Michael Spedding; John A Peters; Anthony J Harmar Journal: Br J Pharmacol Date: 2013-12 Impact factor: 8.739
Authors: Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman Journal: Genome Biol Date: 2002-06-18 Impact factor: 13.583
Authors: Rían W Manville; Jennifer van der Horst; Kaitlyn E Redford; Benjamin B Katz; Thomas A Jepps; Geoffrey W Abbott Journal: Proc Natl Acad Sci U S A Date: 2019-09-30 Impact factor: 11.205
Authors: Paulo W Pires; Eun-A Ko; Harry A T Pritchard; Michael Rudokas; Evan Yamasaki; Scott Earley Journal: J Physiol Date: 2017-06-01 Impact factor: 5.182
Authors: Jennifer van der Horst; Rian W Manville; Katie Hayes; Morten B Thomsen; Geoffrey W Abbott; Thomas A Jepps Journal: Arterioscler Thromb Vasc Biol Date: 2020-03-19 Impact factor: 8.311
Authors: Makhala M Khammy; Sukhan Kim; Bo H Bentzen; Soojung Lee; Inyeong Choi; Christian Aalkjaer; Thomas A Jepps Journal: Br J Pharmacol Date: 2018-01-05 Impact factor: 8.739
Authors: Vincenzo Barrese; Jennifer B Stott; Hericka B Figueiredo; Aisah A Aubdool; Adrian J Hobbs; Thomas A Jepps; Alister J McNeish; Iain A Greenwood Journal: Hypertension Date: 2018-04-23 Impact factor: 10.190